Castellano | Euskara | Français | English
DAR No 3: Desvenlafaxine. Pristiq® in mayor depressive disorder in adults
Share it
More cost for less...
- Desvenlafaxine is an active metabolite of venlafaxine.
- In three placebo-controlled trials, the results on the reduction in HAM-D17 score were not consistent.
- The most common adverse effects are of gastrointestinal origin or sleep disorders. There are no available long-term safety data.
- In the only head-to-head trial carried out in post-menopause women, desvenlafaxine at high doses did not show superiority versus escitalopram.
- The pharmaceutical company withdrew the application for marketing authorisation after an initial evaluation by the EMA´s CHMP that concluded that desvenlafaxine was less effective than venlafaxine and did not present any advantages with regard to safety.
